Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review

Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review

Background: Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with poor overall survival. Although the first-line standard chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy has yielded positive results with survival prolongation, the efficacy remains unsatisfactory,...

Full description

Bibliographic Details
Main Authors:	Sirui Tan, Jing Yu, Qiyue Huang, Nan Zhou, Xianze Xiong, Hongfeng Gou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Pharmacology
Subjects:	cholangiocarcinoma immunotherapy nab-paclitaxel pembrolizumab tumor microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1037646/full

Similar Items

PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series
by: Sirui Tan, et al.
Published: (2022-11-01)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
by: Yizhao Xie, et al.
Published: (2021-11-01)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
by: Kshitij Domadia, et al.
Published: (2022-01-01)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
by: Ken Kamata, et al.
Published: (2023-09-01)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
by: Francesco Di Costanzo, et al.
Published: (2023-01-01)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01)

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by: Frontiers in Oncology Editorial Office
Published: (2014-10-01)

nab-Paclitaxel for the treatment of pancreatic cancer
by: Kim G
Published: (2017-03-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

Nab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice
by: L. Yu. Vladimirova, et al.
Published: (2019-06-01)

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
by: Nan Zhou, et al.
Published: (2023-08-01)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
by: Sara Pusceddu, et al.
Published: (2019-04-01)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
by: Md Sazzad Hassan, et al.
Published: (2023-07-01)

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis
by: Mahtani RL, et al.
Published: (2018-02-01)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
by: Hisashi Tanaka, et al.
Published: (2017-10-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
by: Annalisa Comandatore, et al.
Published: (2022-01-01)

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
by: I. A. Pokataev, et al.
Published: (2019-12-01)

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
by: Haili Lu, et al.
Published: (2021-07-01)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
by: De Luca R, et al.
Published: (2018-06-01)

Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report
by: Yu L, et al.
Published: (2024-04-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
by: Kunihiko Funaishi, et al.
Published: (2017-06-01)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
by: Ursula M. Vogl, et al.
Published: (2019-01-01)

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
by: Ruihua Xu, et al.
Published: (2017-12-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
by: Junji Tsurutani, et al.
Published: (2021-02-01)

Albumin-bound paclitaxel in the treatment of metastatic breast cancer
by: E V Artamonova
Published: (2017-01-01)

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy
by: Ziyi Yang, et al.
Published: (2022-08-01)

Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis
by: Alyaa Khaled Madeeh, et al.
Published: (2024-01-01)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
by: Elisa Giommoni, et al.
Published: (2021-05-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
by: Anne Steins, et al.
Published: (2017-01-01)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
by: Jianzheng Wang, et al.
Published: (2022-06-01)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
by: Yannan Zhao, et al.
Published: (2018-10-01)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.
by: L. G. Zhukova, et al.
Published: (2018-07-01)

Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses
by: Bryce D. Beutler, et al.
Published: (2015-04-01)

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
by: Stephen V. Liu, MD, et al.
Published: (2023-02-01)

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
by: Jiahui Shen, et al.
Published: (2023-02-01)